in vitro News and Research

RSS

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Embryonic stem (ES) cells, known for their capacity to proliferate indefinitely and differentiate into almost all types of cells including hepatocytes, have raised the hope of cellular replacement therapy for liver failure. There have been several protocols available for hepatic fate specification from ES cells, however, most of the protocols currently used result in low yield or purity of functional hepatocytes. Valproic acid (VPA), a histone deacetylase inhibitor, has been demonstrated to facilitate the hepatic differentiation of mesenchymal stem cells. However, little is know about whether VPA could induce the hepatic differentiation of ES cells.

19 Nov 2009

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

Experts at Virgen del Rocío Hospital (Seville, Spain) have begun a study on pregnancy preeclampsia on a sample of 30 pregnant women with a view to demonstrating whether or not consumption of olive oil by this population group results in lower levels of cytotoxicity (for example, cholesterol) in endothelial cells (arterial wall cells).

19 Nov 2009

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

To help bring greater certainty to the measurement of medication levels in a patient's bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs).

19 Nov 2009

China Medical Technologies announces financial results for second fiscal quarter

China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). The Company's 2009 fiscal year ends on March 31, 2010 ("FY2009").

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

iCAD and AdMeTech Foundation sign a strategic partnership agreement

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem.

19 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Asuragen enters into an exclusive agreement with Life Technologies

Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML).

18 Nov 2009

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. But a revolutionary new wound dressing developed at Tel Aviv University could cut that number dramatically.

18 Nov 2009

GlaxoSmithKline and bioMerieux to develop predictive test for breast cancer treatments

bioMerieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients.

17 Nov 2009

Researchers study different plant substances to "awaken" the latent HIV-1 virus

Researchers from the University of Cadiz and the University of Cordoba study different plant substances to "awaken" the latent HIV-1 virus, immune to the current therapy, and to obtain more effective treatments in the future.

17 Nov 2009

LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs.

17 Nov 2009

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

Is the indefinite expansion of adult cells possible without recourse to stem cell intermediates? The team led by Michael Sieweke at the Centre d'immunologie de Marseille Luminy (Université Aix-Marseille 2 / CNRS / INSERM) has proved that this is the case by achieving the ex vivo regeneration for several months of macrophages, specialized cells in the immune system.

16 Nov 2009

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences, a company focused on misfolded protein diseases, today reported its second quarter operating results and provided an update on the Company's diagnostic and therapeutic programs.

13 Nov 2009

BSI implements plans to expand its medical device Notified Body scope to include IVD devices

BSI, a world-class Notified Body providing regulatory and quality management reviews and product certification for medical devices, is rapidly implementing plans to expand its medical device Notified Body scope to include in vitro diagnostic (IVD) devices.

13 Nov 2009

Researchers find a new way to tackle colon cancer

One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells. By focusing on the differences, researchers at Karolinska Institutet have found a new way of tackling colon cancer. The study is presented in the prestigious journal Cell.

13 Nov 2009

Breast cancer patients who undergo fertility preservation need not delay treatment

A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Food science and clinical science join for the first time in a periodical publication

Springer is founding a new journal Food Digestion, dedicated to a quickly growing area of research - food science combined with the physiology of digestion. The journal will publish two issues in 2010 and increase to four issues in 2011.

13 Nov 2009

in vitro News and Research

VisEn Medical launches two new agents for imaging quantification

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

China Medical Technologies announces financial results for second fiscal quarter

Study: EP4 agonist may reduce gastric bleeding and inflammation

iCAD and AdMeTech Foundation sign a strategic partnership agreement

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Asuragen enters into an exclusive agreement with Life Technologies

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

GlaxoSmithKline and bioMerieux to develop predictive test for breast cancer treatments

Researchers study different plant substances to "awaken" the latent HIV-1 virus

LEAD Therapeutics discovers orally available PARP inhibitor

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

BSI implements plans to expand its medical device Notified Body scope to include IVD devices

Researchers find a new way to tackle colon cancer

Breast cancer patients who undergo fertility preservation need not delay treatment

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Food science and clinical science join for the first time in a periodical publication

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News